Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31533414 | 0.83 | CYP17A1 (0.46) | FGFR1HSD17B1HSD17B2MEN1KMT2A | |
| SCHEMBL16385167 | 0.82 | HSD17B1 (0.52) | TLR8FGFR1HSD17B1HSD17B2ESR2 | |
| SCHEMBL16385243 | 0.81 | TLR8 (0.43) | TLR8FGFR1HSD17B1HSD17B2MEN1 | |
| SCHEMBL16385242 | 0.80 | S1PR1 (0.45) | HSD17B1HSD17B2MEN1KMT2AESR2 | |
| SCHEMBL2666284 | 0.79 | MEN1 (0.40) | FGFR1MEN1KMT2A | |
| SCHEMBL30957376 | 0.78 | MEN1 (0.66) | MEN1KMT2AESR2ESR1TP53 | |
| SCHEMBL31186653 | 0.77 | CYP1A1 (0.46) | MEN1KMT2A | |
| SCHEMBL16385161 | 0.77 | PDGFRB (0.52) | MEN1KMT2AS1PR1 | |
| SCHEMBL3342664 | 0.76 | RAB9A (0.44) | TDP1S1PR1 | |
| SCHEMBL25719743 | 0.76 | HSD17B2 (0.53) | HSD17B1HSD17B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020715-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9888688-B2 | Tetrazolinone compounds and applications thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-02 | — | — | US | disclosed |
| EP-3020715-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015005499-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160150787-A1 | TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF | SOD1, UQCRB, MT-CO1 | TLR8 2871/4885FGFR1 2201/4885HSD17B1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.